MVA expressing modified HIV envelope, Gag, and Pol genes
AssigneesThe Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America as represented by the Secretary Department of the Army
InventorsBernard Moss, Patricia Earl, Linda Wyatt, Leigh Eller, Thomas VanCott, Matthew Harris
Life of this patent
Estimating the term…
Abstract
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
Claims48
A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV env, gag, and pol gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV env gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier, wherein said HIV env, gag, and pol genes are isolatable from an individual infected with Ugandan clade D isolate 99UGA03349, 99UGA07412, or 98UG57128.
An MVA shuttle plasmid comprising pLAS-1 of Appendix 2 or sequence having at least about 90%, 95% or 99.9% identity thereto, or pLAS-2 of Appendix 2 or sequence having at least about 90%, 95% or 99.9% identity thereto.
MVA 1974/NIH Clone 1.
A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV env, gag, and pol gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV env gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier, wherein said HIV env, gag, and pol genes are isolatable from an individual infected with Kenyan clade A isolate 00KE-KER2008, 00KE-KNH1144, or 00KE-KNH1207.
A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV env, gag, and pol gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV env gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier, wherein said HIV env, gag, and pol genes are isolatable from an individual infected with Tanzanian clade C isolate 00TZA-246 or 00TZA-125.
Dependencies are inferred from the claim text.